CY1122312T1 - Παραγωγα 4-υδροξυ-2-φαινυλο-4-1,3-θειαζολ-5-υλομεθανονης σαν ανταγωνιστες tprm8 - Google Patents

Παραγωγα 4-υδροξυ-2-φαινυλο-4-1,3-θειαζολ-5-υλομεθανονης σαν ανταγωνιστες tprm8

Info

Publication number
CY1122312T1
CY1122312T1 CY20191101183T CY191101183T CY1122312T1 CY 1122312 T1 CY1122312 T1 CY 1122312T1 CY 20191101183 T CY20191101183 T CY 20191101183T CY 191101183 T CY191101183 T CY 191101183T CY 1122312 T1 CY1122312 T1 CY 1122312T1
Authority
CY
Cyprus
Prior art keywords
disorders
tprm8
antagonists
hylomethanone
thiazole
Prior art date
Application number
CY20191101183T
Other languages
English (en)
Inventor
Andrea Aramini
Gianluca Bianchini
Samuele Lillini
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of CY1122312T1 publication Critical patent/CY1122312T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε ενώσεις που δρουν σαν ανταγωνιστές του διαύλου κατιόντων ασβεστίου παροδικού δυναμικού του υποδοχέα υπο-οικογένειας Μ μέλος 8 (TPRM8), και οι οποίες έχουν τον τύπο (I). Οι αναφερόμενες ενώσεις είναι χρήσιμες στη θεραπεία ασθενειών που συνδέονται με δραστικότητα TPRM8, όπως πόνος, ισχαιμία, νευροεκφυλισμός, εγκεφαλικό επεισόδιο, ψυχιατρικές διαταραχές, δερματίτιδα, ασθένειες ευερέθιστου εντέρου, επαγόμενες από το ψύχος και/ή επιδεινούμενες αναπνευστικές διαταραχές, ουρολογικές διαταραχές, διαταραχές του κερατοειδούς που συνδέονται με διαταραχές στην παραγωγή των δακρύων και/ή αλλοιωμένος βλεφαρισμός, όπως επιφορά και ξηροφθαλμία.
CY20191101183T 2015-12-21 2019-11-11 Παραγωγα 4-υδροξυ-2-φαινυλο-4-1,3-θειαζολ-5-υλομεθανονης σαν ανταγωνιστες tprm8 CY1122312T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15201788.5A EP3184524A1 (en) 2015-12-21 2015-12-21 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
PCT/EP2016/081567 WO2017108632A1 (en) 2015-12-21 2016-12-16 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists

Publications (1)

Publication Number Publication Date
CY1122312T1 true CY1122312T1 (el) 2021-01-27

Family

ID=54883947

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101183T CY1122312T1 (el) 2015-12-21 2019-11-11 Παραγωγα 4-υδροξυ-2-φαινυλο-4-1,3-θειαζολ-5-υλομεθανονης σαν ανταγωνιστες tprm8

Country Status (18)

Country Link
US (1) US10246448B2 (el)
EP (2) EP3184524A1 (el)
JP (1) JP6908610B2 (el)
CN (1) CN108699053B (el)
AU (1) AU2016378108B9 (el)
CY (1) CY1122312T1 (el)
DK (1) DK3394053T3 (el)
EA (1) EA037845B1 (el)
ES (1) ES2757324T3 (el)
HK (1) HK1257896B (el)
HR (1) HRP20192008T1 (el)
HU (1) HUE046284T2 (el)
LT (1) LT3394053T (el)
PT (1) PT3394053T (el)
RS (1) RS59475B1 (el)
SI (1) SI3394053T1 (el)
WO (1) WO2017108632A1 (el)
ZA (1) ZA201803300B (el)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2015531A (en) 1932-07-25 1935-09-24 Champion Paper & Fibre Co Roll coating machine
US20080214654A1 (en) 2004-10-13 2008-09-04 Bayer Healthcare Ag Substituted Benzyloxy-Phenylmethylamide Derivatives
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
WO2007017094A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
WO2007080109A1 (en) 2006-01-16 2007-07-19 Bayer Healthcare Ag Substituded benzyloxy-phenylmethylurea derivatives
JP5404388B2 (ja) 2006-05-10 2014-01-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷メントール受容体−１拮抗薬
MY153971A (en) * 2007-07-18 2015-04-30 Janssen Pharmaceutica Nv Sulfonamides as trpm8 modulators
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
WO2010125831A1 (en) 2009-05-01 2010-11-04 Raqualia Pharma Inc. Sulfamoyl benzoic acid derivatives as trpm8 antagonists
WO2011109551A2 (en) * 2010-03-03 2011-09-09 Calcimedica Inc. Compounds that modulate intracellular calcium
ES2377785B2 (es) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
EP2481727A1 (en) * 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
CN104220069B (zh) * 2011-12-19 2018-10-02 多姆皮制药公司 Trpm8拮抗剂
JP6200495B2 (ja) * 2013-05-08 2017-09-20 キッセイ薬品工業株式会社 α−置換グリシンアミド誘導体
KR102493005B1 (ko) * 2014-06-23 2023-01-30 돔페 파르마써티씨 에스.피.에이. 신경통, 통증, 만성 폐색성 폐질환 (copd) 및 천식 치료시 trpm8-억제제로서 유용한 2-아릴-4-하이드록시-1,3-티아졸 유도체

Also Published As

Publication number Publication date
HRP20192008T1 (hr) 2020-02-07
SI3394053T1 (sl) 2019-12-31
JP6908610B2 (ja) 2021-07-28
ZA201803300B (en) 2019-07-31
AU2016378108A1 (en) 2018-06-21
AU2016378108B2 (en) 2020-12-17
EP3394053B1 (en) 2019-08-21
RS59475B1 (sr) 2019-12-31
CN108699053B (zh) 2022-01-14
HK1257896B (zh) 2020-06-19
ES2757324T3 (es) 2020-04-28
EP3394053A1 (en) 2018-10-31
CN108699053A (zh) 2018-10-23
LT3394053T (lt) 2019-12-10
EA201891503A1 (ru) 2019-01-31
PT3394053T (pt) 2019-10-31
AU2016378108B9 (en) 2021-01-28
EP3184524A1 (en) 2017-06-28
KR20180095818A (ko) 2018-08-28
JP2018538334A (ja) 2018-12-27
DK3394053T3 (da) 2019-11-18
EA037845B1 (ru) 2021-05-27
US20180319785A1 (en) 2018-11-08
WO2017108632A1 (en) 2017-06-29
HUE046284T2 (hu) 2020-02-28
US10246448B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
CY1123569T1 (el) Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer
CY1124416T1 (el) Συνθεσεις ενωσεων και χρησεις αυτων
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
CY1120273T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση φαρνεσοειδων υποδοχεων χ
CY1121359T1 (el) Ενωσεις ετεροαρυλιου για αναστολη κινασης
CY1124918T1 (el) Ρυθμιστες ccr2
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
BR112017002001A2 (pt) compostos e composição farmacêutica
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
PH12016501570A1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
MX2018001564A (es) Compuestos farmaceuticos.
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CY1120403T1 (el) Ανταγωνιστες trpm8
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
CL2017001181A1 (es) Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4)
WO2015148350A3 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EA201891710A1 (ru) Терапевтические соединения
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
DK3463351T3 (da) Behandling til parkinsons sygdom
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.